Predictive value of DRE reaffirmed in large cohort

Article

Findings from a large study of prospectively evaluated men demonstrate that digital rectal exam is an independent predictor of prostate cancer in men undergoing prostate needle biopsy.

Findings from a large study of prospectively evaluated men demonstrate that digital rectal exam is an independent predictor of prostate cancer in men undergoing prostate needle biopsy.

The trial included data from 914 consecutive men who underwent prostate needle biopsy between January 2000 and July 2004 at Virginia Mason Medical Center, Seattle. All evaluations and biopsies were performed by a single surgeon -- Christopher R. Porter, MD, attending, section of urology and renal transplantation.

The patients ranged in age from 23 to 91 years old (mean, 63.9 years) and had a mean PSA of 11.2 ng/mL. Based on prebiopsy evaluations, 476 men (52%) were considered to have an abnormal DRE. A total of 334 men (36.5%) were found to have cancer on biopsy.

Univariate and multivariate analyses considered a variety of prebiopsy parameters to determine those predictive of prostate cancer on biopsy. DRE had independent predictive value in the multivariate analysis (p=.002) considering the overall cohort and continued be an independent predictor in subset analyses including only men with low and moderate voiding symptoms based on AUA symptom score and in those with PSA levels ranging between 2.5 ng/mL and 10.0 ng/mL.

"There is controversy in the urologic community regarding the value of DRE in men referred for prostate biopsy, as various studies have generated conflicting findings," said Kalyan C. Latchamsetty, MD, a fellow in laparoscopic and urologic oncology at Virginia Mason. "The results from this very large, prospectively evaluated cohort indicate clinicians should continue performing routine physical examinations for prostate cancer screening because DRE is an important predictor."

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.